Evidence map›Paper›PMID 42903462›Full record

ArticlehLife2025

Mucosal adenovirus vaccine Ad5-XBB.1.5 boosting elicits nasal IgA and transiently prevents JN.1 wave infection for less than 6 months in real-world settings.

Yanqun Wang, Peilan Wei, Jingjun Zhang, Tian Tang, Ruoxi Cai, Aiping You, Zhaoyong Zhang, Jiantao Chen, Yuanyuan Zhang, Bin Qu and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in hLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Yanqun WangState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China.
Peilan WeiState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China.
Jingjun ZhangState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China.
Tian TangState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China.
Ruoxi CaiState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China.
Aiping YouState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China.
Zhaoyong ZhangState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China.
Jiantao ChenState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China.
Yuanyuan ZhangState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China.
Bin QuShanghai Institute for Advanced Immunochemical Studies, School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Lei ChenState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China.
Qier ZhongGMU-GIBH Joint School of Life Sciences, Guangzhou Medical University, Guangdong, China.
Xindan XingState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China.
Zhiwei LinHealth and Quarantine Laboratory, State Key Laboratory of Respiratory Disease of Guangzhou Customs District Technology Center, Guangdong, China.
Jingxian ZhaoState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China.
Xingui TianState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China.
Airu ZhuState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China.
Lu ZhangHealth and Quarantine Laboratory, State Key Laboratory of Respiratory Disease of Guangzhou Customs District Technology Center, Guangdong, China.
Jincun ZhaoState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mucosal antibodies are critical for protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by limiting viral replication and transmission. While systemic immunity to SARS-CoV-2 is well-characterized, the durability and protective efficacy of mucosal vaccines, especially during the recent JN.1 wave, are less understood. In this study, we conducted a longitudinal assessment of systemic and nasal immune responses in 34 individuals who had received the inhaled Ad5-XBB.1.5 vaccination at days 0, 7, 14, 28, 90, and 180 post-vaccination, using neutralization assays, immunoglobulin A/G (IgA/IgG) enzyme-linked immunosorbent assay (ELISA), T-cell staining, and Fc-effector function assays. Our results showed that mucosal vaccination preferentially induces IgA responses in both nasal mucosa and systemic circulation, with nasal IgA showing stronger correlation with neutralizing titers than IgG. However, nasal antibody responses declined significantly by 6 months post-vaccination, with most participants experiencing breakthrough infections during the JN.1 wave. Individuals with high pre-existing anti-Ad5 antibodies exhibited reduced vaccine-induced neutralizing responses. The Ad5-XBB.1.5 mucosal vaccine enhanced antigen-specific CD8

Indexed as

Ad5-XBB.1.5JN.1 wavemucosal vaccinenasal immunoglobulin A (IgA)short-term protection

Identifiers

PMID42903462
PMCPMC13681517

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.